Takeda Pharmaceutical Company Limited (BVMF:TAKP34)

Brazil flag Brazil · Delayed Price · Currency is BRL
93.24
-0.45 (-0.48%)
At close: Feb 6, 2026
19.54%
Market Cap289.72B +15.8%
Revenue (ttm)156.84B -2.5%
Net Income3.97B -45.7%
EPS2.48 -45.9%
Shares Outn/a
PE Ratio73.03
Forward PEn/a
Dividend2.82 (3.20%)
Ex-Dividend DateSep 29, 2025
Volume100
Average Volume18
Open93.24
Previous Close93.69
Day's Range93.24 - 93.24
52-Week Range70.80 - 93.69
Beta0.08
RSI70.68
Earnings DateJan 29, 2026

About BVMF:TAKP34

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livte... [Read more]

Sector Healthcare
Founded 1781
Employees 47,455
Stock Exchange Brazil Stock Exchange
Ticker Symbol TAKP34
Full Company Profile

Financial Performance

In fiscal year 2025, BVMF:TAKP34's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY Financial Statements